On Monday, 14th June 2021, Novavax Inc. said, its novel corona virus vaccine had been more than 90 percent effective against the different variety of the concerning variants of the novel corona virus in the clinical trials based in the United States. The company Novavax Inc. said, the clinical trials of its corona virus vaccine included around 30,000 volunteers in the United States and Mexico.
The clinical trials have put the company ‘Novavax Inc.’ on the track for filing for the emergency authorization of its corona virus vaccine in the United States in the third quarter of 2021. The company also said that, its protein-based corona virus vaccine was more than 93 percent effective against the more easily transmissible mutated corona virus variants, which are responsible in causing concerns among the scientists and the public health officials of Unites States.
Dr. Gregory Glenn, head of research and development of Novavax Inc., said, the most concerning mutated corona virus variants that were first identified in India, South Africa and Brazil had also been detected among the volunteers during the clinical trials.
Dr. Gregory Glenn also said, the Novavax’s corona virus vaccine had been 91 percent effective among the volunteers, who were at high risk of severe infection and the vaccine is 100 percent effective in the treatment of moderate and severe cases of novel corona virus.
Novavax Inc. said that, the corona virus vaccine had been generally well tolerated and the side effects of the vaccine including fatigue, headache and muscle pain were generally mild, and only a small number of the volunteers have experienced the severe side effects.
